Pharmacokinetics of golimumab in moderate to severe ulcerative colitis: the GO-KINETIC study-Reference-Cited by-同舟云学术

Pharmacokinetics of golimumab in moderate to severe ulcerative colitis: the GO-KINETIC study

Published:2019-05-27 Issue:6 Volume:54 Page:700-706
ISSN:0036-5521
Container-title:Scandinavian Journal of Gastroenterology
language:en
Short-container-title:Scandinavian Journal of Gastroenterology

Author:

Berends Sophie E.¹²^ORCID,Strik Anne S.¹^ORCID,Jansen Jeroen M.³,de Boer Nanne K.⁴,van Egmond Pleun S.²,Brandse Johannan F.⁴,Mathôt Ron A.²,D’Haens Geert R.¹,Löwenberg Mark¹

Affiliation:

1. Department of Gastroenterology and Hepatology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands;

2. Hospital Pharmacy, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands;

3. Department of Gastroenterology and Hepatology, Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands;

4. Department of Gastroenterology and Hepatology, Amsterdam UMC, Vrije Universiteit Amsterdam, AG&M Research Institute, Amsterdam, Netherlands

Publisher

Informa UK Limited

Subject

Gastroenterology

Link

https://tandfonline.com/doi/pdf/10.1080/00365521.2019.1619828

Reference20 articles.

1. Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis

2. Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis

3. Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis

4. Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies

5. Variability in Golimumab Exposure: A ‘Real-Life’ Observational Study in Active Ulcerative Colitis

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Formation and clearance of TNF–TNF inhibitor complexes during TNF inhibitor treatment;British Journal of Pharmacology;2023-12-05

2. Nutrition, Nutritional Status, Micronutrients Deficiency, and Disease Course of Inflammatory Bowel Disease;Nutrients;2023-08-31

3. Efficacious dosing regimens for anti-TNF therapies in inflammatory bowel disease: where do we stand?;Expert Opinion on Biological Therapy;2023-04-03

4. Effectiveness of golimumab intensification in ulcerative colitis: A multicentric prospective study;Alimentary Pharmacology & Therapeutics;2023-02-27

5. Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease;Frontiers in Medicine;2022-06-15